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ABSTRACT:
One of the concerns in targeted drug therapy is that the inhibition of receptors 
and signaling molecules in tumor cells may also affect similar components in the 
tumor microenvironment or in the immune system, with undefined consequences 
for inhibition of tumor growth. Thus, in addition to its antitumor activity in mice 
and humans, the Ras inhibitor salirasib (S-farnesylthiosalicylic acid, FTS) also 
exhibits anti-inflammatory activity. Here we show three antitumor effects of FTS 
in immune-competent mice with subcutaneous or intracranial tumors. First, FTS 
exhibited antitumor activity in immune-competent, intracranial tumor-bearing mice 
and increased their survival relative to tumor-bearing immune-compromised mice. 
Second, FTS induced an increase in regulatory T cells in mouse splenocytes, but 
the inhibitory effects of FTS on tumor growth were not affected by these Foxp3+ 
T lymphocytes. Third, FTS increased antitumor T-cell reactivity by downregulating 
Foxp3. This caused TGF-β-dependent sensitization of the tumor to the immune system.
INTRODUCTION
Foxp3, a transcription factor mainly expressed in 
CD25+CD4+ regulatory T cells (Tregs) [1], plays a major 
role in maintaining homeostasis in immune regulation 
by inhibiting the proliferation of effector T cells, thereby 
maintaining tolerance and preventing development of 
autoimmune diseases [2]. Recently we showed that 
expression of Foxp3 in T lymphocytes is negatively 
controlled by Ras [3-5]. Accordingly, Ras inhibition in 
lymphocytes, both in vitro and in vivo, induces an increase 
in Foxp3 expression in T cells [3-4]. In line with these 
findings, the Ras inhibitor salirasib (FTS) increases the 
number and function of Foxp3+ Tregs and consequently 
attenuates the progression of autoimmune diseases in 
experimental autoimmune encephalitis, an animal model 
for multiple sclerosis [6-7], and in type 1 diabetes [4, 8]. 
These results supported earlier findings showing effects 
of Ras inhibitors in autoimkmune diseases, including 
experimental autoimmune neuritis (an animal model for 
Guillain-Barré), the MRL/lpr mouse model for lupus, 
and experimental antiphospholipid syndrome in mice 
[9-12].  Notably,  FTS  inhibited  all  isoforms  of  active 
Ras (H-, K-, and N-Ras) and attenuated Ras signaling 
and Ras-dependent cell and tumor growth in animal 
studies [13-14]. In recent clinical trials (phases I and II) 
in patients with pancreatic or nonsmall cell lung cancer, 
FTS  exhibited  marked  efficacy  with  limited  toxicity 
(http://www.concordiapharma.com). Although Foxp3 was 
thought to be unique marker for Tregs [2], it was found to 
be expressed also by nonlymphocytic nonhematopoietic 
cells and by cancer cells [15-16]. Foxp3 expression has 
been demonstrated in breast cancer cells, melanoma cells, 
virally transformed B cells, and in cells derived from a 
variety  of  solid  tumors  [15-18].  The  effects  of  FTS-
induced Ras inhibition on Foxp3 expression in tumor cells 
and its influence on their growth are not known. Our main 
objective in the present work was to examine these effects.
Although Foxp3+ Tregs have been found to have 
positive effects in autoimmune diseases (inhibition of 
T effector cells and attenuation of the disease), their 
accumulation in tumors is associated with unfavorable 
clinical prognosis [19]. Foxp3+ Tregs in tumors inhibit 
activation of the antitumor immune response. Moreover, 
depletion of Foxp3+ Tregs results in activation of CD8+ 
cytotoxic T lymphocytes (CTLs) and enhances their 
infiltration into tumors [19]. These effects are accompanied Oncotarget 2012; 3:  144-157 145 www.impactjournals.com/oncotarget
Figure 1: FTS inhibits GL261 cell proliferation and decreases K-Ras-GTP, P-Erk, P-Akt and Foxp3 in vitro. (A) GL261 
cells were untreated (control) or treated for 3 days with 12.5, 25, 50, or 100 µM FTS, and the cells were then directly counted. A typical 
inhibition curve is shown (means ± SEM, n=5). (B) GL261 cells were treated with FTS for 3 days and then assayed for K-Ras, K-Ras-GTP, 
Erk, P-Erk, Akt, P-Akt and tubulin by SDS-PAGE and western blotting, as described in Methods. Representative blots are shown (left). 
Densitometry for K-Ras-GTP, P-Erk, and P-Akt is presented (means ± SD; right). **, p<0.01 compared with control (n=7). (C) GL261 
cells were treated with FTS or left untreated (control) for 24 hours and then assayed for Foxp3 by flow cytometry (left). Statistical analysis 
of the results is presented as means ± SD (right). ***, p<0.0001 compared with control (n=7). (D) FTS-treated GL261 cells were assayed 
for Foxp3 by western blotting (top). Statistical analysis of the results is presented as means ± SD (bottom). **, p<0.001 compared with 
control (n=7). (E) FTS-treated GL261 cells were assayed for Foxp3 and APRT mRNA by RT-PCR. Representative gels are shown (top). 
Densitometry for Foxp3 (means ± SD) is shown (bottom). *, p<0.05 compared with control (n=5). A.U., arbitrary units.Oncotarget 2012; 3:  144-157 146 www.impactjournals.com/oncotarget
by complete regression of tumors [20-21]. Thus, the two 
major  functional  characteristics  of  FTS,  inhibition  of 
tumor growth and attenuation of autoimmunity, seem 
potentially to pose a therapeutic dilemma. On the one hand 
FTS inhibits cancer cell proliferation and tumor growth 
[23, 24]; on the other hand it upregulates Foxp3+ Tregs 
[3, 4, 5], thereby attenuating autoimmune disease but 
inhibiting the antitumor activity of CTLs [22].
Our working hypothesis in the present study was 
that the functions of Ras in autoimmune diseases differ 
from its functions in cancer. We postulate that in cancer 
FTS has a dual effect: it causes a unique Treg-mediated 
immune response, which has a favorable effect on tumor 
cells while at the same time attenuating tumor-cell growth. 
To test our hypothesis, we examined the effect of FTS on 
tumor growth in immune-compromised and immune-
competent mice. According to our hypothesis, we expected 
to find stronger antitumor activity of FTS in the immune-
competent mice owing to the presence of immune cells in 
these mice.
Glioblastoma (GBM) is one of the commonest and 
most aggressive neoplasms among human primary brain 
tumors [25-26]. Using the mouse glioma cell line GL261 
[27], we examined the growth of these cells in syngeneic 
C57bl/6 immune-competent mice (host) and nude mice.
Our results showed that FTS treatment significantly 
inhibited tumor growth when these GBM cells were 
implanted either subcutaneously (s.c.) or intracranially 
into the immune-competent C57bl/6 mice. Thus, in mice 
with intracranial tumors, FTS not only decreased tumor 
size but also prolonged survival. In tumor-bearing nude 
mice, however, the life span of animals treated with FTS 
did not differ from those that remained untreated. In line 
with our hypothesis, FTS reduced the expression of Foxp3 
in tumor cells. This reduction may have altered the tumor 
microenvironment by enhancing the antitumor immune 
response. These results point to the intriguing possibility 
of a mechanism in which Ras inhibition reduces resistance 
of tumors to immune-mediated protection. These novel 
findings also provide strong support for the treatment of 
Figure 2: FTS inhibits the growth of subcutaneous GL261 tumors and decreases their downstream Ras proteins and 
their Foxp3 levels in vivo. GL261 cells were implanted s.c. in the right flank of C57bl/6 mice, which were then treated for 12 days with 
oral FTS or vehicle. After the mice were killed the volumes and weights of their excised tumors were recorded, as described previously 
[31]. (A) Tumor volumes in FTS-treated and control mice are presented as means ± SEM. *, p<0.05, **, p<0.01 compared with control. (B) 
Tumor weights in FTS-treated and control mice are presented as means ± SEM. *, p<0.05 compared with control. (C) K-Ras, K-Ras-GTP, 
Erk, P-Erk, Akt, P-Akt, Foxp3 and tubulin in tumors, and Foxp3 and tubulin in splenocytes, of FTS-treated (n=10) and vehicle-treated mice 
(n=10) were assayed by immunoblotting. Representative blots are shown (top panel). Densitometry values for K-Ras-GTP, P-Erk, P-Akt, 
and Foxp3 are presented as means ± SEM (bottom panel). *, p<0.05, **, p<0.01, ***, p<0.001 compared with control.Oncotarget 2012; 3:  144-157 147 www.impactjournals.com/oncotarget
human glioblastoma with FTS.
RESULTS
FTS inhibits proliferation of GL261 cells and 
decreases levels of K-Ras-GTP, P-Erk and P-Akt 
in vitro 
GL261 cells are mouse glioma cells that carry point 
mutations in the Kras and p53 genes [27]. These cells 
therefore seemed suitable for studies on the cross-talk 
between cancer cells and immune cells in an immune-
competent syngeneic mouse model.
We first investigated the effect of FTS on GL261 cells 
in vitro. FTS (12.5‒100 µM) inhibited GL261 proliferation 
in a dose-dependent manner (IC50, 43.2±3.3 µM; 4 separate 
experiments, each performed in triplicate; Figure 1A). We 
then examined whether the reduction in cell proliferation 
was associated with downregulation of Ras and its major 
downstream signals. Western blot analysis of viable cells 
with specific Abs revealed that treatment with FTS (50 
µM) decreased the levels of K-Ras-GTP, P-Erk, and P-Akt 
by 48.26%±7.5%, 46.9%±2.67%, and 37.82%±4.02%, 
respectively (Figure 1B).
FTS decreases Foxp3 mRNA and protein 
expression in GL261 cells in vitro
Next we examined whether GL261 cells self-express 
Foxp3, and investigated the possible effect of FTS on any 
such expression. FACS analysis and western blot assays 
with anti-Foxp3 Ab revealed that GL261 cells express 
large amounts of Foxp3 (Figure 1C, D). Treatment with 
50  µM  FTS  for  24  hours  decreased  Foxp3  levels  by 
52.3%±9% and 41.3%±5% as determined by FACS and 
by western blot analysis, respectively (Figure 1C, D). 
The same treatment also resulted in a marked decrease 
in Foxp3 mRNA (by  80%±18.3%;  Figure  1E). These 
results indicated that FTS, as opposed to its effects in T 
lymphocytes [3-4, 8], induces downregulation of Foxp3 
in GL261 glioma cells.
FTS inhibits subcutaneous GL261 tumor growth 
in C57bl/6 mice
Our next aim was to investigate the effect of Ras 
inhibition by FTS on GL261 tumor cells in a syngeneic 
mouse model with a competent immune system. C57bl/6 
mice were implanted s.c. with 2×106 GL261 cells (see 
Methods). After 7 days the mice were randomly divided 
into two groups (n=40 in each group) that were treated 
daily for 12 days with oral FTS (60 mg/kg) or vehicle, 
after which their excised tumors were weighed and 
examined by western blotting and FACS, as described in 
Methods. Figure 2A shows the changes in tumor volumes 
as a function of time. Compared with the control, tumor 
volume  in  the  FTS-treated  immune-competent  mice 
was  significantly  inhibited  (by  69%±5%;  Figure  2A). 
Tumor weight in the FTS-treated mice was decreased by 
47.8%±3.8% relative to controls (Figure 2B).
The  in-vivo results of biochemical analyses of 
K-Ras-GTP, P-Erk, and P-Akt in the excised tumors were 
similar to those obtained in vitro, i.e., their levels were 
significantly decreased (by 47.06%±3.9%, 26.74%±7.05%, 
and  24.45%±5.03%,  respectively;  Figure  2C).  Foxp3 
levels  in  these  glioma  cells  were  also  significantly 
decreased (by 31.88%). However, Foxp3 levels in the 
splenocytes of the same tumor-bearing FTS-treated mice 
were significantly increased (by 69.3%±8.63%; Figure 
2C). This result is in agreement with recent findings that 
FTS upregulates peripheral Foxp3+ regulatory T cells [3-
4, 8].  
Inhibition of GL261 tumor growth by FTS is not 
affected by FTS-induced Foxp3 Tregs
The antitumor response of CD8+ CTLs is weakened 
by an increase in CD25+Foxp3+  Tregs  [19].  Seeing 
that  FTS  causes  an  increase  in  Foxp3  expression  in 
lymphocytes [3-2, 8], we suspected that this might 
interfere with the antitumor effect of FTS. Thus, depletion 
of Tregs by the specific anti-CD25 Ab might induce an 
antitumor immune response and hence enhance the FTS-
induced inhibition of tumor growth [19]. 
To examine this possibility we used C57bl/6 mice 
implanted s.c. with GL261 cells as described above. On 
day 4 after tumor cell implantation the mice were divided 
into three groups. To decrease the number of Tregs, mice 
in the first group (n=8) were injected i.p. with 250 µg of 
anti-CD25 Ab on days 4 and 11. At the same times, mice in 
the second group (control, n=8) received 250 µg of IgG1 
Ab. On day 5, mice in those two groups each received 60 
mg of oral FTS. The third group (n=8) served as a control 
for the FTS treatment and received vehicle only. Tumor 
volumes were determined on days 6, 10, 17 and 21, and 
the data are presented in Figure 3A. Tumor growth was 
inhibited in the two groups of FTS-treated mice, and by 
day 21 the decrease in tumor volume in both of these 
groups relative to the vehicle-treated control was highly 
significant (decrease of 70.25%±19% in the first (anti-
CD25 Ab-treated) group (p<0.05) and 64.69%±15.6% 
(p<0.05)  in  the  second  (anti-IgG1 Ab-treated)  group; 
Figure 3A). However, there was no difference in tumor 
volume between the two FTS-treated groups (Figure 3A), 
suggesting that the specific depletion of CD25+Foxp3+ 
Tregs  did  not  enhance  the  antitumor  activity  of  FTS. 
Importantly, in the anti-CD25 Ab-treated group we 
detected, as expected, a marked decrease in CD25+Foxp3+ Oncotarget 2012; 3:  144-157 148 www.impactjournals.com/oncotarget
Tregs both in the spleens (Figure 3B) and in the tumors 
(Figure 3C) of the treated mice. Thus, the FTS-induced 
presence of Tregs did not interfere with the antitumor 
activity of the drug. This conclusion was supported by the 
results of experiments in which CD25+Foxp3+ Tregs in the 
spleens and in the GL261 tumors of C57bl/6 mice were 
assayed without anti-CD25 Ab and with or without FTS 
treatment (Figure 3D). 
In another experiment, C57bl/6 mice implanted 
s.c. with GL261 cells were treated daily, from 7 days 
after implantation, with FTS or vehicle. On day 18 after 
implantation the mice were killed and CD25+Foxp3+ 
levels  in  their  excised  spleens  and  tumor-infiltrating 
lymphocytes (TIL) were measured by flow cytometry 
(see  Methods).  In  spleens  from  FTS-treated  mice, 
the numbers of CD25+Foxp3+ regulatory T cells had 
increased (by 203.7%±9.3% relative to controls; Figure 
3D), in agreement with our previously reported results 
[3-4, 8]. However, treatment with FTS had no effect on 
the numbers of CD25+Foxp3+ Tregs in the tumors (Figure 
3D), indicating that Tregs did not migrate to the tumors or 
proliferate as a result of FTS treatment. Quantification of 
the results is shown in Figure 3D.
FTS decreases secretion of the immunosuppressive 
cytokine TGF-β from GL261 cells 
The lack of involvement of the immune system’s 
regulatory arm in the antitumor activity of FTS (Figure 
3), together with the finding that Foxp3 in GL261 glioma 
cells was decreased after FTS treatment, suggested that 
the Foxp3-depleted GL261 glioma cells might behave 
like lymphocytes, and accordingly produce a pro-
inflammatory  microenvironment.  To  pursue  this  idea, 
we studied the possible involvement of the immune 
system’s inflammatory arm; more specifically, we wanted 
to  find  whether  the  FTS-induced  downregulation  of 
Foxp3 expression observed in GL261 cells (see Figure 
2) has implications for the activity of CD8+ T cells. To 
Figure 3: Inhibition of GL261 tumor growth by FTS is not affected by FTS-induced Foxp3 Tregs. (A-C) C57bl/6 mice 
were implanted s.c. with GL261 cells, treated with FTS and anti-CD25 Ab, or FTS and anti-IgG, or vehicle only, and were killed on day 21, 
as described in Results. (A) Tumor volumes, measured during and at the end of treatment, are shown as means ± SEM. *, p<0.05 compared 
with control (untreated) mice. (B) CD25+Foxp3+ T cells in the spleen were assayed by flow cytometry. Statistical analysis of the results, 
presented as means ± SEM, shows that cell numbers in anti-CD25-treated mice were decreased by 44.55%±5.3% and by 47.54%±8.6% 
compared with anti-IgG1-treated and untreated control mice, respectively). ***, p<0.001 in both cases. (C) CD25+Foxp3+ T cells in tumors 
were assayed by flow cytometry. Statistical analysis of the results, presented as means ± SEM, shows that cell numbers in anti-CD25-treated 
mice were decreased by 28%±7.6% and by 36.03%±3% compared with anti-IgG1-treated and untreated control mice, respectively). ***, 
p<0.0001 in both cases. (D) C57bl/6 mice were implanted with GL261 cells and were then separated into two groups, treated daily with FTS 
or vehicle (control), and killed on day 21, as described in Results. Their excised spleens and GL261 tumors were assayed for CD25+Foxp3+ 
by flow cytometry (upper panel). Statistical analysis of the results is shown (lower panel). ***, p<0.001 compared with control. Oncotarget 2012; 3:  144-157 149 www.impactjournals.com/oncotarget
examine this possibility, we first isolated CD8+ T cells 
from the spleens of GL261-tumor-bearing mice treated 
with FTS for 1 week, and labeled the isolated cells with 
the fluorescent dye carboxyfluorescein succinimidyl ester 
(CFSE; see Materials and Methods). We then added them 
to GL261 cells that had been pretreated for 24 h with 
vehicle or increasing doses of FTS and then thoroughly 
washed. Figure 4 shows that after 96 hours, CD8+ T cells 
incubated with the FTS-pretreated GL261 cells attained 
significantly  higher  proliferation  rates  than  CD8+ T 
cells incubated with untreated control GL261 cells. The 
rate was dose dependent, yielding an increase in CD8+ 
T cells proliferation of 153.3%±1.55%, 184.8%±6.3%, 
and 228.8%±6.6% in the presence of 12.5, 25 and 50 
µM FTS, respectively (Figure 4A). Similar results were 
obtained when we used transwells to separate the CD8+ T 
cells from the GL261 cells and treated the cells with the 
same FTS dosages as above. In this case, the proliferation 
rates of CD8+ T cells were increased by 175.6%±13.51%, 
270.2%±5.4%, and 267.56%±2.7%, respectively, relative 
to controls (Figure 4B). These results suggested that FTS 
reduces  an  anti-inflammatory  response  in  the  GL261 
cells, and that this FTS effect might be mediated by a 
small soluble molecule that is secreted into the media and 
diffuses through the transwells. 
Our next task, therefore, was to identify this putative 
soluble anti-inflammatory molecule. We considered that 
a possible candidate might be transforming growth factor 
(TGF)-β, well known as an anti-inflammatory cytokine 
with a pivotal role in the growth and progression of 
gliomas [28]. Notably, glioma cells are known to induce 
immune suppression via the production of interleukin-10 
(IL-10) and TGF-β [29]. We recently showed, moreover, 
that  FTS  directly  perturbs  TGF-β  signaling  to  Smad-
dependent and Erk-dependent pathways in neurofibromin-
deficient cells [30]. We therefore examined the effect of 
FTS on the secretion of TGF-β from GL261 cells (see 
Methods). We found that FTS induced a dose-dependent 
decrease  in  TGF-β  secretion  from  GL261  cells  (by 
9.82%±0.76%, 17.52%±1.27%, and 42.67%±7.63% in 
the presence of 12.5, 25 and 50 M FTS, respectively;, 
Figure 4C). Accordingly, we postulated that the increase 
in proliferation of CD8+ T cells observed after their 
incubation with FTS-pretreated GL261 cells (Figure 4A, 
B) reflects a decrease in TGF-β secretion. 
To find out whether the abovementioned CD8+ T 
cells contribute to the growth-inhibitory effect of FTS on 
the GL261 cells, we cocultured the CD8+ T cells (isolated, 
as described above, from FTS-pretreated GL261 tumor-
bearing mice) with FTS-pretreated GL261 cells for 96 
hours, then removed the CD8+ T cells and analyzed the 
viability of the GL261 cells (see Materials and Methods). 
The FTS-pretreated GL261 cells that were co-cultured 
with CD8+ T cells exhibited significantly lower viability 
than GL261 cells that were not incubated with CD8+ T 
cells (Figure 4D). The IC50 of FTS-pretreated GL261 cells 
that were incubated with CD8+ cells was significantly 
lower than that of the nonincubated FTS-pretreated GL261 
cells (14.27±1.3 µM vs. 34.87±3.4 µM FTS, Figure 4D). 
Taken together, these results demonstrated that growth 
inhibition by FTS enhances the cytotoxicity of CD8+ T 
cells. 
To support the apparent connection between the 
enhanced proliferative and cytotoxic capacities of CD8+ 
T  cells  and  the  presence  of  the  TGF-β  cytokine,  we 
examined the proliferative and the cytotoxic effects of 
CD8+ T cells with and without neutralization of the TGF-β 
expression from GL261 cells. TGF-β was neutralized as 
described in Methods. The results (Figure 4E, F) show 
that neutralization of the TGF-β expressed by GL261 cells 
indeed significantly increased the proliferation of CD8+ T 
cells (by 175.23%±33.62, Figure 4E) and decreased their 
cytotoxic activity (a decrease of 79.5%±4.65, Figure 4F). 
The neutralization percentage of TGF-β in GL261 cells 
was 72% (data not shown).
FTS increases the accumulation of CD8+ CTLs 
within GL261 tumors
Having  established  that  FTS  enhances  both  the 
proliferative and the cytotoxic effects of CD8+ CTLs in 
vitro, we wanted to find out whether FTS had the same 
effect on these T cells in vivo. We examined whether FTS 
affects the accumulation of CD8+ T cells in peripheral 
GL261 tumors and in the spleens of FTS-treated mice. Our 
results show that FTS significantly increased the numbers 
of CD8+ CTLs in the tumors (by 144.9%±7.78%, p<0.05; 
Figure 4G), identifying FTS as a positive regulator of the 
migration and accumulation of CD8+ CTLs in the tumors. 
However,  no  significant  differences  between  CD8+ T 
cell numbers were observed in the spleens of FTS- and 
vehicle-treated (control) mice (Figure 4G). Thus, unlike 
the effect of FTS in enhancing the splenic production of 
Tregs, FTS had no such effect on the splenic production 
of CTLs.
FTS prolongs survival of intracranial immune-
competent tumor-bearing mice but not of tumor-
bearing nude mice
As mentioned earlier, GL261 cells were chosen for 
the present experiments to examine the effects of FTS with 
and without immune system involvement. Previous studies 
have shown that FTS is able to inhibit intracranial U87 
glioblastoma cell growth in nude mice but not to prolong 
their survival [31]. In the present study we compared 
the effect of FTS on GL261 glioma intracranial tumors 
in immune-competent (C57bl/6 mice) with its effect in 
immune-compromised mice (nude mice). GL261 cells 
were implanted into the crania of nude mice and of 
C57bl/6 mice (syngeneic hosts), as described in Methods. Oncotarget 2012; 3:  144-157 150 www.impactjournals.com/oncotarget
Four days later we divided the mice randomly into two 
groups (n=8 per group). Mice in one group were treated 
with oral FTS (60 mg/kg) and the other (control) with 
the carboxymethyl cellulose vehicle. Tumor growth was 
assessed  by  gadolinium-DTPA-enhanced  T1-weighted 
MRI (see Materials and Methods) on days 10, 14 and 17 in 
C57bl/6 mice and on days 13 and 21 in nude mice. Typical 
images presented in Figure 5A (immune-competent mice) 
and Figure 5C (nude mice) indicate that tumor growth 
was attenuated in both models. However, FTS exerted 
a significantly stronger inhibitory effect in the immune-
competent C57bl/6 mice than in the nude mice. In C57bl/6 
mice the tumor volume was decreased by 66.6%±3.44% 
and 59.67%±15.89%, respectively, on days 14 and 17 
(p<0.01 on both days, Figure 5A). The decrease in the 
nude mice was smaller (only 43.57%±19.58% on day 21; 
p<0.05, Figure 5C). 
It is important to note that FTS treatment increased 
Figure 4: FTS decreases secretion of the 
immunosuppressive  cytokine  TGF-β  from 
GL261 glioma cells and increases the 
proliferative and cytotoxic capacities of 
CTLs  in vitro as well as accumulation of 
CTLs in the tumors in vivo. (A) GL261 tumor 
cells were treated in vitro for 24 hours with FTS or 
CD8 or both, as described in Results. The cells were 
then washed thoroughly, and CFSE-labeled CD8+ 
T cells, (isolated from FTS- or vehicle-pretreated 
GL261 tumor-bearing mouse splenocytes) were 
added and cocultured with the FTS-pretreated GL261 
cells for 96 hours. The rate of CTL proliferation was 
measured  by  flow  cytometry.  Statistical  analysis 
of the results is presented as means ± SEM (n=8). 
***, p<0.001 compared with vehicle-treated mice. 
(B) The experiment was performed as in A, except 
that the CD8+ T cells were now separated from the 
GL261 tumor cells by a transwell, preventing cell 
passage. The rate of CD8+ T cell proliferation was 
measured by flow cytometry. Statistical analysis of 
the results is presented as means ± SEM (n=8). ***, 
p<0.001 compared with vehicle-treated mice. (C) 
GL261 tumor cells were treated with the indicated 
doses of FTS or with vehicle (control) for 24 hours 
and  then  assayed  for  TGF-β  (see  Methods).  The 
ELISA  results  are  shown  (means  ±  SEM,  n=8). 
***, p<0.001 compared with vehicle-treated control 
cells. (D) Isolated CD8+ T cells were cocultured 
with FTS-pretreated GL261 cells for 96 hours and 
their proliferation was analyzed, as described in 
Methods. Numbers of viable CTLs are presented 
as means ± SEM (n=8). *, p<0.05, ***, p<0.001 
compared with vehicle-treated cells. (E-F) GL261 
tumor  cells  were  incubated  with  CFSE-labeled-
CD8+ T cells, with or without TGF-β-blocking anti-
TGF-β Ab, for 96 hours. The rate of CD8+ T cell 
proliferation was measured by flow cytometry (E), 
and viable GL261 cells were counted (F). Statistical 
analysis of the results is presented as means ± SEM 
(n=5). ***, p<0.001 compared with cells not treated 
with anti-TGF-β Ab. (G) C57bl/6 mice implanted 
s.c. with GL261 tumor cells were divided into two 
groups for treatment with FTS (n=10) or vehicle 
(n=10), as described in Methods. The mice were 
killed 21 days after the cells were implanted and 
their tumors and spleens were assayed for CD8+ T 
cells by flow cytometry (left and middle). Statistical 
analysis  of  the  flow  cytometry  results  (n=10)  is 
presented (right). *, p<0.05 compared with vehicle-
treated controls.Oncotarget 2012; 3:  144-157 151 www.impactjournals.com/oncotarget
Figure 5: FTS inhibits intracranial tumor growth and prolongs survival of intracranial immune-competent tumor-
bearing mice but not of the tumor-bearing nude mice. GL261 cells were implanted into the crania of C57bl/6 immune-competent 
and nude mice. Mice were treated and their survival was assessed as described in Results. Gadolinium-enhanced regions were defined and 
their volume (in mm3) and were accumulated. (A) Representative images of brains of immune-competent and nude mice are presented (top 
panel) (n=8 in each group). Statistical analysis of the results is presented as means ± SEM (bottom, left). * p<0.05, ** p<0.01 compared 
with vehicle-treated controls. (B) Survival of the intracranial tumor-bearing immune-competent mice (n=8 in each group) was monitored 
and Kaplan-Meier survival curves are presented; p=0.007, log-rank significance test. (C) Representative images of brains of nude mice are 
presented (top panel) (n=8 in each group). Statistical analysis of the results is presented as means ± SEM (bottom, left). ** p<0.01 compared 
with vehicle-treated controls. (D) Survival of the intracranial tumor-bearing nude mice (n=8 in each group) was monitored and Kaplan-
Meier survival curves are presented; p=0.415, log-rank significance test.Oncotarget 2012; 3:  144-157 152 www.impactjournals.com/oncotarget
survival rates only in the immune-competent C57bl/6 mice 
(p=0.007, log-rank significance test; Figure 5B). Kaplan-
Meier survival curves obtained in these experiments are 
presented in Figure 5B (C57bl/6 mice) and Figure 5D 
(nude mice).  
DISCUSSION
The concept of selective targeting of signal 
transduction pathways has been developed over the past 
few years and has proved highly successful. Thus, anti-
Bcr Abl drugs (e.g. imatinib), anti-epidermal growth 
factor receptor drugs (e.g. Erbitux and Tarceva®), anti-
ERB2 drugs (e.g. trastuzumab) or anti-VEGF receptor 
drugs (e.g. bevacizumab, semaxanib) have been developed 
and approved for a variety of cancer types [32, 33-36]. 
Other drugs, not only against receptors but also against 
their downstream targets, are now being developed. 
These drugs include the Ras inhibitor salirasib (FTS), for 
which clinical phase I and II clinical trials were recently 
completed in patients with pancreatic or NSCLC. Ras 
oncogene products that are targeted by FTS are involved 
in more than 30% of all human tumors [37]. They are 
therefore considered to be good targets for cancer therapy 
[38].
An interesting question with regard to targeted 
drug therapy has to do with the way in which nontumor 
cells and tissues cope with the drug-induced inhibition 
Figure 6: Proposed mechanism explaining the differential effects of Ras inhibition on immune and cancer cells. Ras 
inhibition by FTS acts differently on Foxp3 expression in immune cells and in cancer cells. In immune cells, Ras regulates Foxp3 expression 
via the MAPK pathway. Its inhibition results in upregulation of Foxp3 expression, thereby augmenting Foxp3+ regulatory T cells (Tregs) 
[3-4]. The upregulated CD25+Foxp3+ Tregs induce an anti-inflammatory effect by secreting tolerogenic cytokines, such as IL-10 and 
TGF-β, which attenuate the proliferation of effector T cells and thus help to maintain immune tolerance [42]. In the glioma cancer cells, Ras 
regulates Foxp3 expression via both the MAPK and the PI3K pathways. Treatment of the cancer cells with FTS results in downregulation 
of Foxp3, which in turn attenuates expression of the immunosuppressive cytokine TGF-β from glioma cells. A similar effect of Foxp3 
on TGF-β expression levels has been demonstrated in melanoma cells [43]. The decrease in TGF-β produces an inflammatory tumor 
microenvironment, which promotes robust proliferation, migration, and activation of antitumor CTLs. This effect on the CTLs intensifies 
their antitumor character, resulting in decreased tumor growth.Oncotarget 2012; 3:  144-157 153 www.impactjournals.com/oncotarget
of major growth and differentiation pathways. The 
coping mechanisms of the immune system and the 
microenvironment are of particular interest because of 
the involvement of these systems in tumor growth [39]. 
The various drugs inhibit, either directly or indirectly, 
many signaling molecules in these systems, including 
MAP  kinases,  Akt,  cyclin-dependent  kinases,  and 
small GTPases [40]. These inhibitory activities seem to 
introduce contradictory situations: on the one hand they 
might reduce the antitumor activity of many targeted 
drugs, while on the other hand they support some of 
their antitumor activity, for example by enhancing the 
antitumor activity of the immune system. One example 
of possible contradictory effects is given by FTS, which 
exhibits potent antitumor activity in mice [23-24] and in 
humans (http://www.concordiapharma.com), and a strong 
anti-inflammatory activity in mice [3]. The results of the 
present study showed, however, that Ras inhibition by FTS 
in mice provides a favorable antitumor environment both 
in the immune system and in glioma cells. FTS was found 
here to have three major effects in immune-competent 
tumor-bearing mice. First, it exhibited antitumor activity 
and increased survival of immune-competent mice with 
intracranial gliomas (Figure 5). Notably, the increased 
survival of immune-competent C57bl/6 mice relative to 
nude mice was apparently a function of the presence or 
absence of an intact immune system, rather than of strain 
differences. For example, we previously reported that FTS 
treatment of intracranial U87 gliomas failed to achieve 
increased survival in nude mice [31]. Those results, like 
the present findings, indicated that the increase in survival 
was prevented not by the type of tumor or the strain of 
mouse, but by an incompetent immune system. Second, 
FTS was found to induce an increase in the antitumor 
reactivity of CD8+  CTLs  by  downregulating  TGF-β 
expression in GL261 glioma cells (Figure 4). We attributed 
this effect, in the present study, to the reduction in Foxp3 
resulting from FTS treatment of the tumors in immune-
competent mice (see scheme in Figure 6). Interestingly, 
we have also observed a decrease in Foxp3 in DLD1 
colon cancer cells in vitro (unpublished data), suggesting 
that the effect of FTS on cancer cells that express Foxp3 
might be more general than previously supposed. Third, in 
tumor-bearing immune-competent mice, an FTS-induced 
increase in Tregs was observed in splenocytes (Figure 2). 
Such an increase has also been reported in other mouse 
strains besides C57bl/6, including Balb/c, and NOD [3-4, 
7-8]. Importantly, although FTS was found here to induce 
an increase in the Tregs of the splenocytes in C57bl/6 
mice, no such effect was observed in the tumors (Figure 3). 
In addition, depletion of peripheral CD25+Foxp3+ Tregs in 
tumor-bearing mice did not enhance the tumor-inhibitory 
effect of FTS. Evidently, therefore, Foxp3+ Tregs do not 
interfere with the inhibitory effects of FTS. These novel 
findings demonstrated the antitumor activity of FTS in 
immune-competent mice. They also demonstrated the 
negative involvement of Foxp3 in glioma and showed 
that inhibition of Foxp3 by FTS has a favorable antitumor 
activity. 
Taken together, our results suggest that the impact of 
FTS-induced Ras inhibition (Figures 1 and 2) on Foxp3 
expression in the immune system differs from its impact 
on Foxp3 expression in cancer cells. In the immune cells 
it leads to upregulation of Foxp3, whereas in cancer cells 
it leads to Foxp3 downregulation (see scheme in Figure. 
6). The outcome of Ras inhibition in immune cells is 
an  enhanced  anti-inflammatory  response  (increased 
interleukin-10 and TGF-β) and immune tolerance [7]. 
Its outcome in GL261 glioma tumor cells, however, is 
decreased secretion of TGF-β and hence an increase in the 
proliferation and functional capacity of antitumor CD8+ 
CTLs (see Figure 4 and scheme in Figure 6). All in all, our 
results highlight the importance of the immune system, 
and probably also of the tumor microenvironment, in 
supporting tumor growth. They also support a mechanism 
by which Ras inhibition in glioma cells changes the 
tumor microenvironment in a way that reduces resistance 
of the tumor to the immune system and hence induces 
significantly increased inhibition of cancer growth. 
The importance of these results derives from the 
fact that they can explain some of the major beneficial 
effects of Ras inhibitors, as well as of inhibitors that act 
downstream of Ras. Moreover, these beneficial effects 
are not restricted to inhibition of tumor growth, but also 
relate to the microenvironment and the immune system. 
These are novel findings, which provide, in addition, an 
experimental framework for examining the impact of 
other anticancer drugs on cancer and the immune system. 
Such experiments can be used for the design of drug 
combinations of anticancer and immunostimulatory drugs.
MATERIALS AND METHODS
Cell culture and reagents
The glioma cell line GL261 was a generous gift from 
the laboratory of Prof. Reuven Stein. The GL261 cell 
line and splenocytes were cultured in DMEM and RPMI 
medium, respectively, supplemented with 10% fetal calf 
serum  (Biological  Industries,  Kibbutz  Beit  Ha-Emek, 
Israel), 100 U/ml penicillin and 100 U/ml streptomycin, in 
a humidified environment with 5% CO2 at 37oC. FTS was 
a gift from Concordia Pharmaceuticals (Fort Lauderdale, 
FL). 
Western blotting and GTPase pull-down assays
GL261 cells were plated at a density of 1×106 cells 
per 10-cm plate, grown for 24 hours, and then treated with 
FTS or 0.1% Me2SO4 (control). Cells were then lysed in Oncotarget 2012; 3:  144-157 154 www.impactjournals.com/oncotarget
300 µl of homogenization buffer [41], centrifuged for 
10 minutes at 14 000 rpm at 4°C, and the supernatant 
was collected. Equal amounts of proteins (50–100 µg 
per  lane)  were  subjected  to  SDS-PAGE,  followed  by 
immunoblotting with the following antibodies (Abs): 
mouse  anti-Pan-Ras  (Ab-3)  monoclonal  Ab  (mAb) 
(Calbiochem, San Diego, CA), anti-CD3 (AbD Serotec, 
Oxford, UK), anti-Erk (Santa Cruz Biotechnology, CA), 
anti-P-Erk  (Sigma,  St.  Louis,  MO),  anti-Akt,  anti-P-
AKT (Cell Signaling, Danvers, MA), anti-tubulin, and 
anti-Foxp3 (eBioScience, San Diego, CA). Blots were 
exposed to the appropriate secondary peroxidase-coupled 
IgG (Jackson ImmunoResearch Laboratories, West Grove, 
PA)  and  subjected  to  enhanced  chemiluminescence 
(Amersham Pharmacia Biotech, Piscataway, NJ). Protein 
bands  were  quantified  by  densitometry  with  Image 
EZQuant-Gel Statistical Analysis Software. Ras-GTP in 
the lysates was assayed by the glutathione-S-transferase 
– Ras-binding domain (GST-RBD) pull-down assay, and 
this was followed by western blotting with anti-Pan-Ras 
(Ab-3) mAb.
Determination of Foxp3 expression
RNA was extracted from 1×106 GL261 glioma 
cells  using  the  RNeasy  Mini  Kit  (Qiagen,  Hilden, 
Germany) according to the manufacturer’s protocol. 
Reverse  transcription  (RT)-PCR  was  performed 
according to the protocol of the Reverse-iT™ 
1st  Strand  Synthesis  Kit  (ABgene,  Epsom,  UK). 
Adenosine  phosphoribosyltransferase  (APRT)  was 
analyzed  using  the  following  primers: APRT  forward 
5′-GCCTCTTGGCCAGTCACCTGA-3′  and  APRT 
reverse  5′-CCAGGCTCACACACTCCACCA-3′.  PCR 
was  carried  out  with  ReddyMix™  PCR  Master  Mix 
(ABgene) on a Programmable Thermal Controller (MJ 
Research,  Waltham,  MA)  at  gene-specific  conditions. 
Primer sequences for Foxp3 were: Foxp3 forward 5′- 
CACCCAGGAAAGACAGAACC -3′ and Foxp3 reverse 
5′-  GCAAGAGCTCTTGTCCATTGA  -3′.  The  PCR 
products were subjected to electrophoresis in 2% agarose 
gel stained with ethidium bromide.
Cell separation and flow cytometry
Spleens and GL261 tumor tissues were removed 
from C57bl/6 mice and single-cell suspensions were 
stained  with  either  phycoerythrin  (PE)-labeled  anti-
CD25  (BC96)  mAb  or  PE-labeled  anti-CD8  (LY-2) 
mAb. Foxp3 was stained according to the manufacturer’s 
instructions (eBioscience). Stained cells were analyzed by 
FACSCalibur (BD Biosciences, San Diego, CA). CD8+ 
cells were isolated from splenocytes by the BD FACSAria 
cell sorter (BD Biosciences). 
Cell division tracking and coculturing assays 
The isolated CD8+ cells were harvested, washed 
twice in cold PBS, resuspended in PBS at a concentration 
of 5×106 cells/ml, and stained (for assessment of their 
proliferation rates) by incubation for 10 minutes at 
37°C  with  the  fluorescent  dye  carboxyfluorescein 
succinimidyl ester (CFSE; 5-( and 6)-carboxyfluorescein 
diacetate  succinimidyl  ester;  BD  Biosciences;  5  mM, 
diluted 1/1000). The staining reaction was stopped by 
two washes with complete medium. The stained CD8+ 
cells (1×105 per well) were then cocultured with GL261 
cells (1×104 per well) pretreated with 12.5, 25, or 50 
µM FTS in RPMI medium for 96 hours in the presence 
of 2.5 µg/ml anti-CD28 (37.51) and 5 µg/ml anti-CD3e 
(145-2C11) monoclonal antibodies (eBioscience). In 
other  experiments,  we  separated  the  CFSE-stained 
CD8+ cells from the GL261 cells by using 24-well 
translucent chambers, pore size 0.4 μm (Greiner Bio-One, 
Frickenhausen, Germany). FTS-pretreated GL261 cells 
(1×104 per well) were seeded in the lower chamber in 500 
μl RPMI, and the isolated and CFSE-stained CD8+ cells 
were placed on top of the membrane (1×104 per well) in 
200 μl RPMI. After 96 hours the supernatant media of the 
isolated and the nonisolated cultures were collected and 
proliferation of the CFSE-labeled CD8+ T cells in both 
sets of cultures was analyzed by flow cytometry in three 
independent experiments. All migration experiments were 
carried out in duplicate.
Neutralization of TGF-β
Anti-TGF-β1 mAb (R & D Systems, Ellisville, MO; 
1 µg/ml) was used as a blocking antibody to neutralize the 
activity of TGF-β in vitro.
Assay of TGF-β cytokine
Secretion of TGF-β from GL261 cells treated for 
24 hours with 12.5, 25, or 50 µM FTS was measured by 
ELISA (Linco Research, St. Charles, MO).
In-vivo studies
The study was approved by the Institutional Ethics 
Committee at the Tel Aviv Sourasky Medical Center, Tel 
Aviv, Israel (Approval ID: L-11-019 for C57bl/6 mice; 
L-11-024 for athymic nude mice).Oncotarget 2012; 3:  144-157 155 www.impactjournals.com/oncotarget
Subcutaneous implantation of GL261 cells into 
C57bl/6 mice
C57bl/6 male mice (8-10 weeks old) were housed as 
described earlier [7]. On day 0, GL261 cells (2×106 cells 
in 0.1 ml PBS) were implanted s.c. just proximal to the 
right femur. After 7 days, by which time tumor volumes 
(measured as previously described [41]) were 0.3–0.5 
cm3, mice were separated randomly into two groups (40 
mice per group). Mice in one group were treated daily 
with oral FTS, 60 mg/kg, and mice in the other group 
received vehicle (carboxymethyl cellulose). After 18 days 
the mice were killed. Tumors were weighed and were then 
homogenized for western blotting and FACS analysis as 
described above.
Intracranial implantation of GL261 glioma cells 
into C57bl/6 and nude mice
Male C57bl/6 mice (4 months old) and athymic 
nude  mice  (8‒10  weeks  old)  were  anesthetized  by 
intraperitoneal (i.p.) injection of ketamine (100 mg/kg) 
and xylazine (20 mg/kg) and then placed in a stereotaxic 
alignment system (Kopf Instruments, CA). A cut, 
approximately 1 cm long, was made in the scalp, exposing 
the skull, and a 2-mm burr hole was drilled 1 mm posterior 
to the bregma and 1.5 mm lateral to it. A Hamilton 10-
µl syringe and a 31-gauge Hamilton needle were used to 
implant 1×105 GL261 cells in 3 µl DMEM, 3 mm below 
the surface of the cortex, at a rate of 1 µl/min. To avoid 
backflow, the needle was left for an additional 1 minute 
before being gradually removed. The scalp was stitched 
and the mice were allowed to recover in their cages. 
Survival rates of the tumor-bearing mice were recorded.
Magnetic resonance imaging
At 10, 14, and 17 days after intracranial implantation 
of GL261 cells, tumor progression was assessed by 
magnetic resonance imaging (MRI) as described earlier 
[31]. The MRI scans were performed under inhalational 
isoflurane  (1%–2%)  anesthesia  (Nicholas  Piramal 
(Mumbai, India) in 98% oxygen. Immediately before 
scanning the mice were injected i.p. with 150 µl of 0.1M 
Gd-DTPA (Soreq Radiopharmaceuticals, Yavne, Israel). 
Mice were scanned in a 7T/30 spectrometer (Bruker 
Biospin, Ettlingen, Germany) using a quadrature head 
coil and a 400 mT/m gradient system. The MRI protocol 
included gadolinium (Gd)-DTPA-enhanced T1 weighted 
imaging (TR=800 and TE=12 ms); field of view 2×2 cm; 
matrix dimensions 256×128 (reconstructed to 256×256) 
pixels). Fourteen slices, 0.8 mm thick with no gap, were 
acquired in the coronal orientation. Final image resolution 
was 0.078×0.078×1 mm3. The tumor area was determined 
using the Medical Image Analysis version 2.4 in MATLAB 
(Mathworks, MA).
Survival analysis
Following their intracranial implantation with 
GL261 cells, mice were monitored and weighed daily until 
they died. Survival curves were calculated by the Kaplan-
Meier procedure. The log-rank test was used for statistical 
analysis.
Downregulation of Foxp3+ CD25+ cells in vivo
Regulatory T cells in vivo were decreased by 
injection  of  purified  anti-CD25 Ab,  which  blocks  the 
production of CD25+ cells (Tregs). Anti-CD25 Ab was 
contributed by Prof. Jacob George’s lab. GL261 cells were 
implanted s.c. in the flanks of C57bl/6 mice on day 0, as 
above. On day 4 the tumor-bearing mice were divided into 
three groups. In two of the groups each mouse was injected 
i.p. on days 4 and 11, in the first group with 250 µg of 
purified anti-CD25 Ab and in the second group with 250 
µg of functional grade purified IgG1 Ab (eBioscience). 
From day 5, both groups received FTS treatment. The 
mice in the third group did not receive antibody and were 
treated with the vehicle (control) instead of FTS. Tumors 
were measured on days 6, 10, 17, and 21.
Statistical analysis
Descriptive analytical data are presented as means 
±  SEM.  Tumor  volumes  were  compared  by  two-way 
ANOVA (repeated measures). Survival was assessed by 
Kaplan-Meier survival analysis followed by a log-rank 
test. The results of all other experiments were analyzed by 
unpaired Student’s t-test and one-way ANOVA. Values of 
p<0.05 were considered statistically significant. 
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